Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FCE 23762

Known as: FCE-23762 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
FCE 23762 (3′ desamino-3′[2(s)methoxyl-4-morpholinyl]doxorubicin) is a new doxorubicin (Dx) derivative that has been selected for… Expand
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
2000
2000
We conducted a clinical evaluation of FCE 23762, a methoxymorpholino analog of doxorubicin, in 48 dogs with metastatic… Expand
Is this relevant?
1997
1997
BACKGROUND 3'-Deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) is a highly lipophilic doxorubicin… Expand
Is this relevant?
1995
1995
Methoxymorpholinyldoxorubicin (FCE 23762) is a novel, highly lipophilic doxorubicin analogue. It possesses potent in vitro and in… Expand
Is this relevant?
1993
1993
The purpose of this study was to examine the cytotoxicity and cardiotoxicity of the new doxorubicin derivative, 3'-deamino-3'-(2… Expand
Is this relevant?
1993
1993
A simple, rapid and reproducible high-performance thin-layer chromatographic (HPTLC) method using UV or fluorescence scanning… Expand
Is this relevant?
1992
1992
FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety… Expand
  • figure 1
  • table I
  • table IV
  • table II
  • table III
Is this relevant?